Skip to search formSkip to main contentSkip to account menu

Zalypsis

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

PM 00104

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
Despite improvements in the prognosis of multiple myeloma (MM) associated with the recent introduction of immunomodulatory drugs… 
2014
2014
Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen
AbstractPurposeThis exploratory phase II clinical trial evaluated the antitumor activity, safety profile and pharmacokinetics of… 
2013
2013
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
SummaryPM00104 (Zalypsis®) is a new synthetic alkaloid with potent cytotoxic activity against tumor cell lines. This phase I… 
2013
2013
Phase II study of weekly PM00104 (ZALYPSIS®) in patients with pretreated advanced/metastatic endometrial or cervical cancer
This open-label, two-arm, phase II clinical trial evaluated the antitumor activity and safety profile of PM00104 (Zalypsis… 
2013
2013
A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
PurposePM00104 (Zalypsis®) is a synthetic tetrahydroisoquinoline alkaloid with potent antiproliferative activity against tumor… 
2011
2011
Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients
ObjectiveThe aim of this study was to characterize the population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients… 
2010
2010
Development of an in vitro model for the simultaneous study of the efficacy and hematotoxicity of antileukemic compounds.
2008
2008
DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity
Background and Aims: Although recent therapeutic advances have led to an improvement in the outcome of Multiple Myeloma (MM), it… 
2007
2007
Genome-wide screen reveals antitumor Zalypsis® as a strong inducer of DNA double strand breaks
AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 5733 Zalypsis® (PM00104) is a novel synthetic antineoplastic agent… 
2006
2006
Toxicokinetic evaluation of a novel anti-tumor agent, Zalypsis® (PM00104), in dogs
3095 Zalypsis® (PM00104) is a new synthetic alkaloid related to Jorumycin and Renieramycins. Preliminary insights into the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)